CAS 1254036-71-9

1H-Indazole, 6-(1H-indol-4-yl)-4-[5-[[4-(1-methylethyl)-1-piperazinyl]methyl]-2-oxazolyl]-

CAS: 1254036-71-9

Fórmula: C₂₆H₂₈N₆O

Pureza: 99%

Forma y color: Solid

Peso molecular: 440.5401

Ref: IN-DA000NMT

Nemiralisib

CAS: 1254036-71-9

Nemiralisib

Pureza: ≥98%

Peso molecular: 440.54g/mol

Ref: 54-BUP02013

Nemiralisib

CAS: 1254036-71-9

Nemiralisib is a small molecule that inhibits the PD-L1 protein. It can be used to treat cancer and autoimmune diseases. Nemiralisib binds to the PD-L1 protein and prevents it from binding to its ligands, CD80 or CD86. This prevents the immune system from being suppressed by the PD-L1 protein and may enable an anti-PD-L1 therapy to induce tumor regression in patients with cancer. Nemiralisib has been shown to inhibit P-glycoprotein (Pgp) activity in vitro, which may result in drug interactions with other drugs that are substrates of this transporter. Nemiralisib has a terminal half life of approximately 6 hours, meaning that most of it will be eliminated from the body within 24 hours after administration. The chemical name for nemiralisib is 1-[3-(4-chlorophenyl)phenyl]-3-[2-(methylsulfonyl)phenyl]urea. The

Fórmula: C₂₆H₂₈N₆O

Pureza: Min. 95%

Peso molecular: 440.54 g/mol

Ref: 3D-EAC03671

Nemiralisib

CAS: 1254036-71-9

Nemiralisib (GSK-2269557) is an oral PI3Kδ inhibitor (pKi 9.9) for treating respiratory diseases like COPD.

Fórmula: C₂₆H₂₈N₆O

Pureza: 99.91%

Forma y color: Solid

Peso molecular: 440.54

Ref: TM-T15431